MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds

thought leadership

ISPOR 2024: insights from our policy, access, value, and evidence experts


From attending a thought-provoking ISPOR 2024 conference in Atlanta, it’s clear that the biopharmaceutical and diagnostic industries are experiencing a period of rapid change; policies are evolving, payer environments are shifting, the concept of value is expanding, and great science is no guarantee of frictionless, in-market patient access.

This summary of our daily insights from ISPOR 2024 tackles some of these questions: specifically, our expert perspectives on building a patient-centric value story, navigating competing evidence requirements across markets, amplifying and scaling data value, and early pipeline planning for the new realities of the market.


Embracing a patient-centric approach, collaborating closely with patients and advocacy groups, and recognizing the transformative influence of patient insights will be critical for success in navigating the evolving global landscape and making science accessible to every patient. Meet our team at ISPOR 2024 to continue the conversation

Philip Drew

Head of Global Partnerships

avatar for Philip Drew - Head of Global Partnerships


Patient centricity: a crucial approach for access, value, and evidence

The landscape of commercial development and market access is constantly evolving, with patient engagement playing a crucial role in shaping these trends. Here are the key take-aways discussed at ISPOR 2024 with the Avalere Health team:

  • Growing recognition of patient-centric approaches: Biopharmaceutical manufacturers are increasingly acknowledging the importance of patients as consumers and recognizing the need to understand patients’ own definitions of value and valuable treatments. This recognition strengthens the entire product development cycle, with patients contributing to study design.
  • Influence on regulatory and HTA activities: Regulators and HTA agencies are increasingly incorporating patient insights into their assessments. Patient preference data from rigorously conducted studies provides decision-makers with a wider pool of views on outcomes that patients value. The US FDA’s new guidance on gathering patient input underscores the growing significance of patient involvement in regulatory processes, as does the EUnetHTA 2021 guidance.
  • Transformation of patient groups into expert influencers: Patients are leveraging their exposure to regulatory and HTA activities to drive policy changes, challenge industry practices, and find solutions for accessing high-cost treatments. Initiatives such as the European Patients’ Academy on Therapeutic Innovation (EUPATI) are educating and training patient advocates to engage in drug development and market access.

Given these trends, it’s essential to consider the following:

  • Early engagement with patients: Engage with patient advocacy groups early in product development to ensure their perspectives are integrated throughout the process.
  • Long-term partnerships: Establish long-term partnerships between manufacturers and patient/advocacy groups to successfully incorporate the patient voice into product development.
  • Understanding patient preferences: Invest in understanding patient preferences through rigorous studies to support regulatory submissions effectively.

Embracing a patient-centric approach, collaborating closely with patients and advocacy groups, and recognizing the transformative influence of patient insights will be critical for success in navigating the evolving global landscape and making science accessible to every patient.


Please get in touch

To continue the conversation, or read more

Contact us


Within early pipeline planning, the realities of evolving global markets are prompting new questions: how do I prioritize indications for a new asset to balance price, access, and volume across different markets? How will payers react and assess product value in prioritized markets? Meet our team at ISPOR 2024 for insights to navigate these complex challenges.

Jan McKendrick

Executive Director and Practice Lead, Global HEOR

avatar for Jan McKendrick - Executive Director and Practice Lead, Global HEOR


Early pipeline: new realities of the market

Value-based decision-making early in the clinical development cycle is crucial given the substantial investment required to conduct clinical trials on the path to commercialization. Scientific breakthroughs are propelling an increase in regulatory approvals, driving the need for evidence that determines the value of a drug to ensure successful patient access. Approaches that evaluate the market access potential can also inform the strategy for pipeline assets.

Here are the key take-aways discussed at ISPOR 2024 with the Avalere Health team:

  • Real-world evidence is playing an increasing role in validating trial outcomes, providing context for economic modeling assumptions, including natural history of disease, and contextualizing reimbursement decisions.
  • Budget scrutiny over newly launched products may be leading to complex managed entry agreements and a growing focus on achieving better value for money.
  • Demand is growing for qualitative but also increasingly quantitative economic insights from rapid early economic modeling and evaluation to contribute critical insights.

Recommendations include:

  • Right-size your approach to market access to ensure informed insights during early clinical development.
  • Prioritize resources for meaningful input into clinical development and strategic decision-making.
  • Incorporate critical HEOR insights early and often for more informed decisions on pipeline asset with tools like hēRo3


Get in touch

To continue the conversation or watch our on-demand webinar for additional insights for right sizing your approach to market access in early clinical development:

Contact us


Value requirements are becoming more complex, and understanding this complexity is critical for both value and overall business strategies. How should I think about my pipeline and associated development plans? Is the additional risk associated with increased value differentiation justified by pricing and access gains? How do I shape my access strategy to support divergent value requirements? Integrating these considerations is critical for success.

Michael Ciarametaro

Managing Director, Policy

avatar for Michael Ciarametaro - Managing Director, Policy



Evidence: navigating competing requirements across markets

The evidence and value landscape has expanded in complexity, leading to increased and diverging requirements for evidence strategies. Avalere Health experts continued the conversation started during our Monday theater presentation, “No longer business as usual: establishing value in an uncertain and dynamic landscape,” today at #ISPORAnnual. These recent value developments don’t occur in isolation, furthering the complexities facing life sciences companies.


  • IRA implementation: The IRA substantially changed the HEOR landscape, requiring shifting strategies to ensure preparation for new evidence needs. As the first negotiation cycle wraps up, there are opportunities to leverage learnings for the future. Separately, what does the redesign of the Part D benefit mean for value? How does this differ by plan and therapeutic area?
  • PDABs and other state drug price control initiatives: PDABs may evaluate the affordability of drugs earlier in the product lifecycle than CMS during negotiation, leading to questions about the impact of these earlier assessments on evidence planning. Further, PDAB methodologies vary from state to state, where certain approaches could present greater portfolio risks.
  • Joint clinical assessments: With JCA implementation starting in 2025, manufacturers need to prepare for a rapidly evolving pricing and reimbursement landscape in the EU. Early pipeline planning, evidence generation strategies, incorporation of tighter timelines, launch sequencing, and market prioritization are some of the most top-of-mind concerns stakeholders must consider.
  • Upcoming US election and potential changes to drug pricing legislation: Potential changes tied to 2024 US election outcomes will have very different implications for the drug pricing political landscape, leading to questions about the future of the IRA and other drug pricing legislation. How will outcomes differ by election outcome scenario? What are the implications for ex-US markets?
  • Value framework application and implications: Value assessors continue to leverage different metrics and explore the application of new methods (eg, GRACE, lifecycle value assessment), leading to questions around the implications for life sciences companies and how this should shape strategies.


Get in touch

To continue the conversation or read more

Contact us


Data assets: amplifying and scaling data value


Data assets: amplifying and scaling data value


As the breadth, depth, and content of data in healthcare are continuously growing, the industry needs to make data actionable and leverage it to make intelligent business decisions. As ISPOR 2024 concludes, Avalere Health experts are wrapping up the conversations with one last, but not least, focus area: amplifying and scaling data value.


Here are the key take-aways discussed today at #ISPORAnnual with the Avalere Health team:


  • Health equity and social determinants of health: Analysis of data related to social and behavioral factors, as well as through a health equity lens, is a key strategic approach that can help organizations minimize incomplete decision-making based on partial evidence. By integrating data on health equity and social determinants of health with clinical and claims data, stakeholders gain a more comprehensive understanding of patient populations and the patient journey while developing targeted interventions and allocating resources more effectively.
  • Economic burden of disease: Calculating the total burden of illness or determining the economic impact of a disease at various levels—whether patient, caregiver, healthcare system, and/or societal—may be challenging. However, a robust dataset and well-designed research strategy can offer useful insights and context for patients, caregivers, payers, health technology assessment agencies, healthcare providers, policymakers, manufacturers, researchers, and society.
  • Data ecosystems: An optimal data ecosystem can improve decision-making processes within an organization by centralizing and standardizing data from different sources. The application of artificial intelligence and machine learning to healthcare may help align the healthcare systems to quality care and drive positive patient and societal outcomes.
  • Novel approaches to data generation: As real-world evidence continues to drive the research discussions and decisions in healthcare, stakeholders need to keep up with the pace of innovation to increase clinical research efficiency and develop targeted strategies to enhance value stories and provide compelling evidence for stakeholder engagement. Full understanding of novel real-world data sources and innovative technologies to gather, process, and analyze them creates a need for a more robust approach to creating real-world evidence.


Exploring ways to incorporate data into daily functions, investing in new ways to provide healthcare to patients, and incorporating real-world evidence into business decisions can help the industry deliver better healthcare to those who need it the most.


Get in touch

Get in touch with us to continue the conversation, or read more

Contact us

We care about your privacy

By clicking "Accept all cookies", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

Manage my preferences

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Avalere Health website, such as the pages you visit.

For more information, check the cookie statement


Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.